Carrying Through in Advanced/Metastatic Urothelial Carcinoma: Expert Perspectives on Recent Practice‐Changing Data and the Practicalities of Individualizing and Continuing Care With Novel Immunotherapy Maintenance Strategies

1.00 hr(s) | CME

Specialty: urothelial carcinoma (UC)

Therapeutic Area(s): Oncology , Urologic oncology

Release Date: December 29, 2021

Expiration Date: December 28, 2022

Location: Internet Activity Enduring

Improving outcomes for patients with advanced urothelial carcinoma (UC) has been challenging, with many patients experiencing only short periods of progression-free survival after treatment with first-line chemotherapy. A game changer in many cancers, immunotherapy has provided new avenues for the cancer care team to help their patients with advanced UC live longer. In particular, new data on the use of immunotherapy in the first-line maintenance setting has shown that using immunotherapy before patients’ progress to the second-line setting increases survival without a negative impact on quality of life. In this activity, a panel of experts discusses strategies for incorporating these important data into individualized patient care.

Access this activity
Share via
Copy link
Powered by Social Snap